 |
|
The Anticholinergic Risk Scale and Anticholinergic Adverse Effects in Older Persons
James L. Rudolph, MD, SM;
Marci J. Salow, PharmD;
Michael C. Angelini, MA, PharmD;
Regina E. McGlinchey, PhD
Arch Intern Med. 2008;168(5):508-513.
Background Adverse effects of anticholinergic medications may contribute to events such as falls, delirium, and cognitive impairment in older patients. To further assess this risk, we developed the Anticholinergic Risk Scale (ARS), a ranked categorical list of commonly prescribed medications with anticholinergic potential. The objective of this study was to determine if the ARS score could be used to predict the risk of anticholinergic adverse effects in a geriatric evaluation and management (GEM) cohort and in a primary care cohort.
Methods Medical records of 132 GEM patients were reviewed retrospectively for medications included on the ARS and their resultant possible anticholinergic adverse effects. Prospectively, we enrolled 117 patients, 65 years or older, in primary care clinics; performed medication reconciliation; and asked about anticholinergic adverse effects. The relationship between the ARS score and the risk of anticholinergic adverse effects was assessed using Poisson regression analysis.
Results Higher ARS scores were associated with increased risk of anticholinergic adverse effects in the GEM cohort (crude relative risk [RR], 1.5; 95% confidence interval [CI], 1.3-1.8) and in the primary care cohort (crude RR, 1.9; 95% CI, 1.5-2.4). After adjustment for age and the number of medications, higher ARS scores increased the risk of anticholinergic adverse effects in the GEM cohort (adjusted RR, 1.3; 95% CI, 1.1-1.6; c statistic, 0.74) and in the primary care cohort (adjusted RR, 1.9; 95% CI, 1.5-2.5; c statistic, 0.77).
Conclusion Higher ARS scores are associated with statistically significantly increased risk of anticholinergic adverse effects in older patients.
Author Affiliations: Geriatric Research, Education, and Clinical Center, Veterans Affairs Boston Healthcare System (Drs Rudolph, Salow, Angelini, and McGlinchey), Division of Aging, Department of Medicine, Brigham and Women's Hospital (Drs Rudolph and McGlinchey), Massachusetts College of Pharmacy (Dr Angelini), and Departments of Medicine (Dr Rudolph) and Psychiatry (Dr McGlinchey), Harvard Medical School, Boston.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Measures of Drug Toxicity in Older Adults
Sarah N. Hilmer and Darrell R. Abernethy
Arch Intern Med. 2008;168(17):1930-1931.
EXTRACT
| FULL TEXT
Measures of Drug Toxicity in Older Adults—Reply
James L. Rudolph, Marci J. Salow, Michael C. Angelini, and Regina E. McGlinchey
Arch Intern Med. 2008;168(17):1931-1932.
EXTRACT
| FULL TEXT
Limitations of the Anticholinergic Risk Scale
Madan Kwatra
Arch Intern Med. 2008;168(21):2386.
EXTRACT
| FULL TEXT
Limitations of the Anticholinergic Risk Scale—Reply
James L. Rudolph, Marci J. Salow, Michael C. Angelini, and Regina E. McGlinchey
Arch Intern Med. 2008;168(21):2386.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Predicting the onset of delirium in the post-operative patient
Noimark
Age Ageing 2009;38:368-373.
ABSTRACT
| FULL TEXT
Limitations of the Anticholinergic Risk Scale
Kwatra
Arch Intern Med 2008;168:2386-2386.
FULL TEXT
Limitations of the Anticholinergic Risk Scale--Reply
Rudolph et al.
Arch Intern Med 2008;168:2386-2386.
FULL TEXT
Diagnosis and treatment of dementia: 4. Approach to management of mild to moderate dementia
Hogan et al.
CMAJ 2008;179:787-793.
ABSTRACT
| FULL TEXT
Measures of Drug Toxicity in Older Adults--Reply
Rudolph et al.
Arch Intern Med 2008;168:1931-1932.
FULL TEXT
Measures of Drug Toxicity in Older Adults
Hilmer and Abernethy
Arch Intern Med 2008;168:1930-1931.
FULL TEXT
|
